Citations

Clear

7551 citation(s) found for "Ho, Matthew".

LRRC10 is required to maintain cardiac function in response to pressure overload
Brody, Matthew J. , Feng, Li , Grimes, Adrian C., Hacker, Timothy A. , Olson, Timothy M. , Kamp, Timothy J. , Balijepalli, Ravi C. , Lee, Young-Sook, Kamp, Timothy J , Olson, Timothy M

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | November 26, 2015 | Volume: 310 | Issue: 2 | Pages: H269-H278

10.1152/ajpheart.00717.2014 | PMID 26608339 Get It

We previously reported that the cardiomyocyte-specific leucine-rich repeat containing protein (LRRC)10 has critical functions in the mammalian heart. In the present study, we tested the role of LRRC10 in the response of the heart to biomechanical stress by performing transverse aortic constriction on Lrrc10-null ( Lrrc10−/−) mice. Mild pressure overload induced severe cardiac dysfunction and ventricular dilation in Lrrc10−/−mice compared with control mice. In addition to dilation and cardiomyopathy, Lrrc10−/−mice showed a pronounced increase in heart weight with pressure overload stimulation and a more dramatic loss of cardiac ventricular performance, collectively suggesting that the absence of LRRC10 renders the heart more disease prone with greater hypertrophy and structural remodeling, although rates of cardiac fibrosis and myocyte dropout were not different from control mice. Lrrc10−/−cardiomyocytes also exhibited reduced contractility in response to β-adrenergic stimulation, consistent with loss of cardiac ventricular performance after pressure overload. We have previously shown that LRRC10 interacts with actin in the heart. Here, we show that His150of LRRC10 was required for an interaction with actin, and this interaction was reduced after pressure overload, suggesting an integral role for LRRC10 in the response of the heart to mechanical stress. Importantly, these experiments demonstrated that LRRC10 is required to maintain cardiac performance in response to pressure overload and suggest that dysregulated expression or mutation of LRRC10 may greatly sensitize human patients to more severe cardiac disease in conditions such as chronic hypertension or aortic stenosis.
Subparaneurial ganglion cysts of the fibular and tibial nerves: A new variant of intraneural ganglion cysts
Prasad, Nikhil , Desy, Nicholas M. , Howe, B. Matthew, Amrami, Kimberly K. , Spinner, Robert J. , Prasad, Nikhil K.

Mayo Clinic

Clinical Anatomy | November 24, 2015 | Volume: 29 | Issue: 4 | Pages: 530-537

10.1002/ca.22671 | PMID 26599204 Get It

Over the last decade, the mechanism of formation of intraneural ganglion cysts has been established through a meticulous review of clinical findings and correlation with patterns produced on magnetic resonance imaging (MRI). Pathognomonic imaging patterns distinguish these rare lesions from the more common extraneural variants in almost all cases. In this report, we present a new pattern of cyst occurrence in the subparaneurial compartment of the nerve and provide potential anatomic explanations for its pathogenesis. Using an anatomic framework of connective tissue compartments of the nerve, we reviewed 63 (56 fibular and seven tibial) intraneural ganglion cysts in the knee region evaluated at our institution and all reports with MRI in the world's literature for evidence of cyst occurrence in the subparaneurial compartment. We identified six cases (five in the common fibular nerve and one in the tibial nerve) at our institution that had MR evidence of cyst in the subparaneurial compartment with a new complex lobulated pattern. All cases had articular branch connections to the superior tibiofibular joint, which at operation were resected along with the joints. Follow‐up revealed complete recovery in all instances and no clinical or radiological signs of recurrence. Three cases out of 80 in the literature exhibited the new complex lobulated MRI pattern. We present a new pattern of intraneural ganglion cyst occurrence in a potential space that surrounds peripheral nerves‐ the subparaneurial compartment. We believe that the unifying articular theory applies to the pathogenesis and management of these rare variants. Clin. Anat. 29:530–537, 2016. © 2015 Wiley Periodicals, Inc.
Volumetric analysis of tumor control following subtotal and near‐total resection of vestibular schwannoma
Jacob, Jeffrey T. , Carlson, Matthew L. , Driscoll, Colin L. W., Link, Michael J. , Driscoll, Colin L.

Mayo Clinic

The Laryngoscope | November 24, 2015 | Volume: 126 | Issue: 8 | Pages: 1877-1882

10.1002/lary.25779 | PMID 27426941 Get It

Objectives/HypothesisThe primary goals of microsurgery for vestibular schwannoma (VS) include preservation of neural function and complete tumor removal. In a subset of patients, adherent tumor remnant may be intentionally left behind in order to minimize risk of new neurologic deficits. It is not well established if residual tumor volume predicts likelihood of tumor remnant growth.MethodsPatients with sporadic VS who underwent near‐total (NTR) or subtotal (STR) VS resection between 2000 and 2014 were reviewed. Postoperative tumor remnants were volumetrically contoured using T1‐weighted gadolinium‐enhanced magnetic resonance imaging obtained within 3 months of surgery.ResultsA total of 103 patients met study criteria, and the median duration of radiographic follow‐up was 41 months (mean 56.1 months, range 12–150 months). Fifty patients underwent NTR and 53 received STR. Overall 14 (13.6%) tumors recurred at a median of 41.0 months. Patients who underwent STR were over 13 times more likely to recur compared with those treated with NTR (hazard ratio 13.31; 95% confidence interval 1.71–103.91; P = 0.014). The median time to recurrence following NTR was 124 months compared to 32 months after STR (P < 0.001).ConclusionsLong‐term follow‐up in patients undergoing incomplete resection is essential. Near‐total resection has a significantly lower rate of recurrence compared to STR. Maximal surgical resection should be the goal in VS microsurgery. The decision to pursue less than complete resection should be based on intraoperative impression, when it is felt that continued dissection of adherent disease would compromise neurologic outcome.Level of Evidence4. Laryngoscope, 126:1877–1882, 2016
Crowdsourcing Assessment of Surgeon Dissection of Renal Artery and Vein During Robotic Partial Nephrectomy: A Novel Approach for Quantitative Assessment of Surgical Performance
Powers, Mary K., Boonjindasup, Aaron, Pinsky, Michael R. , Dorsey, Philip, Maddox, Michael, Su, Li-Ming, Gettman, Matthew T., Sundaram, Chandru P. , Castle, Erik P., Lee, Jason Y. , Gettman, Matthew, Lee, Benjamin R.

Mayo Clinic

Journal of Endourology | November 24, 2015 | Volume: 30 | Issue: 4 | Pages: 447-452

10.1089/end.2015.0665 | PMID 26597352 Get It

Adverse Event Rates Associated with Transforaminal and Interlaminar Epidural Steroid Injections: A Multi-Institutional Study
El-Yahchouchi, Christine, Plastaras, Christopher T. , Maus, Timothy P. , McCormick, Zachary L. , Geske, Jennifer R. , Smuck, Matthew , Pingree, Matthew J. , Kennedy, David J. , Carr, Carrie M. , Geske, Jennifer

Mayo Clinic

Pain Medicine | November 23, 2015 | Volume: 17 | Issue: 2 | Pages: 239-247

10.1111/pme.12896 | PMID 26593277 Get It

Abstract Background. Transforaminal epidural steroid injections (TFESI) have demonstrated efficacy and effectiveness in treatment of radicular pain. Despite little evidence of efficacy/effectiveness, interlaminar epidural steroid injections (ILESI) are advocated by some as primary therapy for radicular pain due to purported greater safety. Objective. To assess immediate and delayed adverse event rates of TFESI and ILESI injections at three academic medical centers utilizing International Spine Intervention Society practice guidelines. Methods. Quality assurance databases from a Radiology and two physical medicine and rehabilitation (PM&R) practices were interrogated. Medical records were reviewed, verifying immediate and delayed adverse events. Results. There were no immediate major adverse events of neurologic injury or hemorrhage in 16,638 consecutive procedures in all spine segments (14,956 TFESI; 1,682 ILESI). Vasovagal reactions occurred in 1.2% of procedures, more frequently ( P = 0.004) in TFESI (1.3%) than ILESI (0.5%). Dural punctures occurred in 0.06% of procedures, more commonly after ILESI (0.2% vs 0.04%, P = 0.006). Delayed follow up on PM&R patients (92.5% and 78.5, next business day) and radiology patients (63.1%, 2 weeks) identified no major adverse events of neurologic injury, hemorrhage, or infection. There were no significant differences in delayed minor adverse event rates. Central steroid response (sleeplessness, flushing, nonpositional headache) was seen in 2.6% of both TFESI and ILESI patients. 2.1% of TFESI and 1.8% of ILESI patients reported increased pain. No long-term sequelae were seen from any immediate or delayed minor adverse event. Conclusions. Both transforaminal and ILESI are safely performed with low immediate and delayed adverse event rates when informed by evidence-based procedural guidelines. By demonstrating comparable safety, this study suggests that the choice between ILESI and TFESIs can be based on documented efficacy and effectiveness and not driven by safety concerns.
Dural arteriovenous fistula-induced thalamic dementia: report of 4 cases
Holekamp, Terrence F., Mollman, Matthew E., Murphy, Rory K. J. , Kolar, Grant R. , Kramer, Neha M. , Derdeyn, Colin P. , Moran, Christopher J. , Perrin, Richard J. , Rich, Keith M. , Zipfel, Gregory J. , Lanzino, Giuseppe , Derdeyn, Colin P

Mayo Clinic

Journal of Neurosurgery | November 20, 2015 | Volume: 124 | Issue: 6 | Pages: 1752-1765

10.3171/2015.5.jns15473 | PMID 26587655 Get It

Nonhemorrhagic neurological deficits are underrecognized symptoms of intracranial dural arteriovenous fistulas (dAVFs) having cortical venous drainage. These symptoms are the consequence of cortical venous hypertension and portend a clinical course with increased risk of neurological morbidity and mortality. One rarely documented and easily misinterpreted type of nonhemorrhagic neurological deficit is progressive dementia, which can result from venous hypertension in the cortex or in bilateral thalami. The latter, which is due to dAVF drainage into the deep venous system, is the less common of these 2 dementia syndromes. Herein, the authors report 4 cases of dAVF with venous drainage into the vein of Galen causing bithalamic edema and rapidly progressive dementia. Two patients were treated successfully with endovascular embolization, and the other 2 patients were treated successfully with endovascular embolization followed by surgery. The radiographic abnormalities and presenting symptoms rapidly resolved after dAVF obliteration in all 4 cases. Detailed descriptions of these 4 cases are presented along with a critical review of 15 previously reported cases. In our analysis of these 19 published cases, the following were emphasized: 1) the clinical and radiographic differences between dAVF-induced thalamic versus cortical dementia syndromes; 2) the differential diagnosis and necessary radiographic workup for patients presenting with a rapidly progressive thalamic dementia syndrome; 3) the frequency at which delays in diagnosis occurred and potentially dangerous and avoidable diagnostic procedures were used; and 4) the rapidity and completeness of symptom resolution following dAVF treatment.
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer
Patnaik, Amita , Haluska, Paul , Erlichman, Charles , Papadopoulos, Kyriakos P. , Lensing, Janet L., Beeram, Muralidhar , Molina, Julian R. , Rasco, Drew , Arcos, Rebecca R., Kelly, Claudia S., Wijayawardana, Sameera R. , Zhang, Xuekui , Bell, Robert L., Shi, Peipei , Kulanthaivel, Palaniappan, Pitou, Celine, Mulle, Lynette B., Farrington, Daphne L., Chan, Edward M. , Tolcher, Anthony W. , Stancato, Louis F. , Bell, Robert, Goetz, Matthew P.

Mayo Clinic

Clinical Cancer Research | November 18, 2015 | Volume: 22 | Issue: 5 | Pages: 1095-1102

10.1158/1078-0432.ccr-15-1718 | PMID 26581242 Get It

Abstract Purpose: p38 MAPK regulates the production of cytokines in the tumor microenvironment and enables cancer cells to survive despite oncogenic stress, radiotherapy, chemotherapy, and targeted therapies. Ralimetinib (LY2228820 dimesylate) is a selective small-molecule inhibitor of p38 MAPK. This phase I study aimed to evaluate the safety and tolerability of ralimetinib, as a single agent and in combination with tamoxifen, when administered orally to patients with advanced cancer. Experimental Design: The study design consisted of a dose-escalation phase performed in a 3+3 design (Part A; n = 54), two dose-confirmation phases [Part B at 420 mg (n = 18) and Part C at 300 mg (n = 8)], and a tumor-specific expansion phase in combination with tamoxifen for women with hormone receptor–positive metastatic breast cancer refractory to aromatase inhibitors (Part D; n = 9). Ralimetinib was administered orally every 12 hours on days 1 to 14 of a 28-day cycle. Results: Eighty-nine patients received ralimetinib at 11 dose levels (10, 20, 40, 65, 90, 120, 160, 200, 300, 420, and 560 mg). Plasma exposure of ralimetinib (Cmax and AUC) increased in a dose-dependent manner. After a single dose, ralimetinib inhibited p38 MAPK–induced phosphorylation of MAPKAP-K2 in peripheral blood mononuclear cells. The most common adverse events, possibly drug-related, included rash, fatigue, nausea, constipation, pruritus, and vomiting. The recommended phase II dose was 300 mg every 12 hours as monotherapy or in combination with tamoxifen. Although no patients achieved a complete response or partial response,19 patients (21.3%) achieved stable disease with a median duration of 3.7 months, with 9 of these patients on study for ≥6 cycles. Conclusions: Ralimetinib demonstrated acceptable safety, tolerability, and pharmacokinetics for patients with advanced cancer. Clin Cancer Res; 22(5); 1095–102. ©2015 AACR.
Preoperative platelet transfusions and perioperative red blood cell requirements in patients with thrombocytopenia undergoing noncardiac surgery
Warner, Matthew A. , Jia, Qing , Clifford, Leanne, Wilson, Gregory , Brown, Michael , Hanson, Andrew C. , Schroeder, Darrell R. , Kor, Daryl J. , Warner, Matthew A , Schroeder, Darrell

Mayo Clinic

Transfusion | November 11, 2015 | Volume: 56 | Issue: 3 | Pages: 682-690

10.1111/trf.13414 | PMID 26559936 Get It

BACKGROUNDPerioperative hemorrhage impacts patient outcomes and health care resource utilization, yet the risks of transfusion therapies are significant. In patients with preoperative thrombocytopenia, the effects of prophylactic preoperative platelet (PLT) transfusion on perioperative bleeding complications remain uncertain.STUDY DESIGN AND METHODSThis is a retrospective cohort study of noncardiac surgical patients between January 1, 2008, and December 31, 2011. Propensity‐adjusted analyses were used to evaluate associations between preoperative thrombocytopenia, preoperative PLT transfusion, and the outcomes of interest, with a primary outcome of perioperative red blood cell (RBC) transfusion.RESULTSA total of 13,978 study participants were included; 860 (6.2%) had a PLT count of not more than 100 × 109/L with 71 (8.3%) receiving PLTs preoperatively. Administration of PLTs was associated with higher rates of perioperative RBC transfusion (66.2% vs. 49.1%, p = 0.0065); however, in propensity‐adjusted analysis there was no significant difference between groups (odds ratio [OR] [95% confidence interval {95% CI}], 1.68 [0.95‐2.99]; p = 0.0764]. Patients receiving PLTs had higher rates of intensive care unit (ICU) admission (OR [95% CI], 1.95 [1.10‐3.46]; p = 0.0224) and longer hospital lengths of stay (estimate [95% bootstrap CI], 7.2 [0.8‐13.9] days; p = 0.0006) in propensity‐adjusted analyses.CONCLUSIONPreoperative PLT transfusion did not attenuate RBC requirements in patients with thrombocytopenia undergoing noncardiac surgery. Moreover, preoperative PLT transfusion was associated with increased ICU admission rates and hospital duration. These findings suggest that more conservative management of preoperative thrombocytopenia may be warranted.
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, Jasvinder A. , Bridges, S. Louis , Bannuru, Raveendhara R. , Sullivan, Matthew C. , Vaysbrot, Elizaveta E., McNaughton, Christine, Osani, Mikala C. , Parks, Deborah, Kavanaugh, Arthur, O’Dell, James R., Leong, Amye , Matteson, Eric L. , Drevlow, Barbara E., Ginsberg, Seth, Grober, James, Clair, E. William St. , Tindall, Elizabeth A., Miller, Amy S., Saag, Kenneth G. , Akl, Elie A. , Shmerling, Robert H. , Curtis, Jeffrey R. , Furst, Daniel E. , King, Charles M. , Schousboe, John T. , Grober, James, McAlindon, Timothy E. , Singh, Jasvinder A , Bannuru, Raveendhara R

Mayo Clinic

Arthritis Care & Research | November 6, 2015 | Volume: 68 | Issue: 1 | Pages: 1-25

10.1002/acr.22783 | PMID 26545825 Get It

ObjectiveTo develop a new evidence‐based, pharmacologic treatment guideline for rheumatoid arthritis (RA).MethodsWe conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence. We employed a group consensus process to grade the strength of recommendations (either strong or conditional). A strong recommendation indicates that clinicians are certain that the benefits of an intervention far outweigh the harms (or vice versa). A conditional recommendation denotes uncertainty over the balance of benefits and harms and/or more significant variability in patient values and preferences.ResultsThe guideline covers the use of traditional disease‐modifying antirheumatic drugs (DMARDs), biologic agents, tofacitinib, and glucocorticoids in early (<6 months) and established (≥6 months) RA. In addition, it provides recommendations on using a treat‐to‐target approach, tapering and discontinuing medications, and the use of biologic agents and DMARDs in patients with hepatitis, congestive heart failure, malignancy, and serious infections. The guideline addresses the use of vaccines in patients starting/receiving DMARDs or biologic agents, screening for tuberculosis in patients starting/receiving biologic agents or tofacitinib, and laboratory monitoring for traditional DMARDs. The guideline includes 74 recommendations: 23% are strong and 77% are conditional.ConclusionThis RA guideline should serve as a tool for clinicians and patients (our two target audiences) for pharmacologic treatment decisions in commonly encountered clinical situations. These recommendations are not prescriptive, and the treatment decisions should be made by physicians and patients through a shared decision‐making process taking into account patients’ values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, Jasvinder A. , Bridges, S. Louis , Bannuru, Raveendhara R. , Sullivan, Matthew C. , Vaysbrot, Elizaveta E., McNaughton, Christine, Osani, Mikala C. , Parks, Deborah, Kavanaugh, Arthur, O’Dell, James R., Leong, Amye , Matteson, Eric L. , Drevlow, Barbara E., Ginsberg, Seth, Grober, James, Clair, E. William St. , Tindall, Elizabeth A., Miller, Amy S., McAlindon, Timothy E. , Saag, Kenneth G. , Akl, Elie A. , Shmerling, Robert H. , Curtis, Jeffrey R. , Furst, Daniel E. , King, Charles M. , Schousboe, John T. , Grober, James, Singh, Jasvinder A , Bannuru, Raveendhara R

Mayo Clinic

Arthritis & Rheumatology | November 6, 2015 | Volume: 68 | Issue: 1 | Pages: 1-26

10.1002/art.39480 | PMID 26545940 Get It

Objective To develop a new evidence‐based, pharmacologic treatment guideline for rheumatoid arthritis (RA). Methods We conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence. We employed a group consensus process to grade the strength of recommendations (either strong or conditional). A strong recommendation indicates that clinicians are certain that the benefits of an intervention far outweigh the harms (or vice versa). A conditional recommendation denotes uncertainty over the balance of benefits and harms and/or more significant variability in patient values and preferences. Results The guideline covers the use of traditional disease‐modifying antirheumatic drugs (DMARDs), biologic agents, tofacitinib, and glucocorticoids in early (<6 months) and established (≥6 months) RA. In addition, it provides recommendations on using a treat‐to‐target approach, tapering and discontinuing medications, and the use of biologic agents and DMARDs in patients with hepatitis, congestive heart failure, malignancy, and serious infections. The guideline addresses the use of vaccines in patients starting/receiving DMARDs or biologic agents, screening for tuberculosis in patients starting/receiving biologic agents or tofacitinib, and laboratory monitoring for traditional DMARDs. The guideline includes 74 recommendations: 23% are strong and 77% are conditional. Conclusion This RA guideline should serve as a tool for clinicians and patients (our two target audiences) for pharmacologic treatment decisions in commonly encountered clinical situations. These recommendations are not prescriptive, and the treatment decisions should be made by physicians and patients through a shared decision‐making process taking into account patients’ values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.